Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized study of talquetamab plus daratumumab with or without pomalidomide versus daratumumab, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma
CTR20223266Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of talquetamab in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Started Feb 2023; status: active.
02
Drugs
talquetamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20223266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223266.